
Zejula 100mg Capsule
Salt Composition: Niraparib
Expiry Date: 01/2028
Inclusive of all taxes
90 capsule
About The Product
Ovarian Cancer
Niraparib 100mg capsule is prescribed by doctors to cure cervical cancer in women. Its generic name is Niraparib.
Description
Zejula 100mg Capsule contains Niraparib as an active ingredient. This anticancer medicine belongs to the class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors. It is prescribed to treat certain types of cancers, primarily ovarian, fallopian tube, and peritoneal cancers.
Also It can be used to treat certain types of cancer in people with specific gene (BRCA) changes. It works by inhibiting the action of PARP enzyme that repairs damaged DNA in the cancer cells, resulting in their death.
Close monitoring of blood cell count is necessary while having treatment with this medicine. Take it in the exact dosage prescribed by the doctor.
Uses
Ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer
Side Effects
The human body reacts differently to Zejula 100mg Capsule. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Capsule are mentioned below:
Nausea and vomiting
Fatigue
Loss of appetite
Constipation
Insomnia
Stomach pain
Headache or dizziness
Serious:
Severe anaemia
Thrombocytopenia
Hypertension
Allergic reactions
Bone marrow suppression
Rare cases of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)
How To Use
- Take Zejula 100mg Capsule in exact dose as prescribed by the doctor.
- The typical dose of this capsule varies with age and overall health factor of the patient.
- It can be taken with or without food but at a fixed time each day to get better results.
- Niraparib capsule should be swallowed as a whole with water without crushing, chewing, or opening the capsule.
- Don't miss a dose or overdose the medicine.
How It Works
Zejula 100mg Capsule contains Rucaparib as an active ingredient. This anticancer medicine belongs to the class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors.
This tablet is an inhibitor of poly Adenosine diphosphate-ribose polymerase enzymes, including PARP-1, PARP-2, and PARP-3, that play a vital role in DNA repair. Niraparib 100mg capsule works by inhibiting the action of specific enzyme that repairs damaged DNA in the cancer cells, resulting in their death.
Safety Advice
Missed Doses
- It is advisable not to miss any dose.
- In case you miss a dose of Niraparib 100mg capsule consult your doctor soon.
- Missing the dose will impact the overall health of the patients.
- So, it is always advisable to follow the prescription of the doctor strictly.
FAQs
Zejula 100mg Capsule is an anti-cancer medication used to treat certain types of cancer such as ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
References
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., ... & Monk, B. J. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology, 20(5), 636-648. https://pubmed.ncbi.nlm.nih.gov/30948273/
Li, N., Zhu, J., Yin, R., Wang, J., Pan, L., Kong, B., ... & Wu, L. (2023). Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA oncology, 9(9), 1230-1237. https://pubmed.ncbi.nlm.nih.gov/37440217/
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., ... & Monk, B. J. (2019). Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 381(25), 2391-2402. https://pubmed.ncbi.nlm.nih.gov/31562799/
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., ... & Matulonis, U. A. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine, 375(22), 2154-2164.
Scott, L. J. (2017). Niraparib: first global approval. Drugs, 77(9), 1029-1034. https://pubmed.ncbi.nlm.nih.gov/28474297/
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
